InMed Pharmaceuticals Inc. INM
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 35.30% | 7.46% | |||
| Depreciation & Amortization | -6.38% | -2.82% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.01% | -4.23% | |||
| Operating Income | -14.01% | -32.81% | |||
| Income Before Tax | -73.48% | -37.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -73.48% | -37.65% | |||
| Earnings from Discontinued Operations | -470.62% | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -96.86% | -46.25% | |||
| EBIT | -14.01% | -32.81% | |||
| EBITDA | -14.35% | -33.78% | |||
| EPS Basic | -49.24% | -42.87% | |||
| Normalized Basic EPS | 13.39% | -34.44% | |||
| EPS Diluted | -49.24% | -42.87% | |||
| Normalized Diluted EPS | 13.39% | -34.44% | |||
| Average Basic Shares Outstanding | 31.90% | 2.37% | |||
| Average Diluted Shares Outstanding | 31.90% | 2.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||